immune response genes

im·mune re·sponse genes

genes in the HLA-D region of the histocompatibility complex of human chromosome 6 that control the immune response to specific antigens.

im·mune re·sponse genes

(i-myūn' rĕ-spons' jēnz)
Genes in the HLA-D region of the histocompatibility complex of human chromosome-6 that control the immune response to specific antigens.

immune response genes

Genes, including all those within the MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) that determine the total response to a given antigen.
References in periodicals archive ?
They found that in helper T (CD4+) cells, the proteins Oct1 and OCA-B work together to put immune response genes on standby so that they are easily activated when the body is re-exposed to a pathogen.
Chronic exposure to arsenic in the drinking water alters the expression of immune response genes in mouse ung.
About half the population is genetically susceptible to celiac disease because they carry the immune response genes HLA-DQ2 or HLA-DQ8.
Association of Marek's disease with Ea-B and immune response genes in subline and F2 populations of the Iowa State S1 Leghorn line.
The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent approximately 70 percent of all MS patients.
The interim analysis included patients from the first 200 to complete MAESTRO-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the trial in MS patients with the target HLA-DR2 and/or HLA-DR4 immune response genes.
Fewer copies of specific immune response genes may increase an individual's risk of contracting HIV and AIDS.
This is thought to ensure that their offspring have as wide a range of immune response genes - and therefore greater protection against infection - as possible.
A cluster of immune response genes called the Major Histocompatibility Complex (MHC) is known to influence pheromones in animals and humans.
According to Newell, "In this article, we demonstrate that a synthetic peptide designed on the basis of its "fit" with the products of immune response genes, can interfere with, and dampen, inflammation associated with some immune conditions.
The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).
The expression of these immune response genes was previously noted to be associated with beneficial clinical response to Melacine treatment in Phase I and II clinical trials.